1346702-54-2 Usage
Uses
Used in Organic Synthesis:
6-BROMO-1-ISOPROPYL-1H-INDAZOLE-4-CARBOXYLIC ACID is used as a key intermediate for the synthesis of complex organic molecules, leveraging its reactive functional groups to facilitate the formation of desired products in chemical reactions.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-BROMO-1-ISOPROPYL-1H-INDAZOLE-4-CARBOXYLIC ACID is utilized as a research compound to explore its potential in the development of new drugs, capitalizing on its unique structural features and pharmacological properties.
Used in Medicinal Chemistry:
6-BROMO-1-ISOPROPYL-1H-INDAZOLE-4-CARBOXYLIC ACID is employed as a building block in medicinal chemistry for the synthesis of bioactive molecules, contributing to drug discovery efforts by providing a foundation for the creation of novel therapeutic agents.
Used as a Precursor for Indazole Derivatives:
6-BROMO-1-ISOPROPYL-1H-INDAZOLE-4-CARBOXYLIC ACID is used as a precursor in the synthesis of other indazole derivatives with potential biological activities, serving as a starting material for the development of compounds with diverse applications in the life sciences.
Check Digit Verification of cas no
The CAS Registry Mumber 1346702-54-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,6,7,0 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1346702-54:
(9*1)+(8*3)+(7*4)+(6*6)+(5*7)+(4*0)+(3*2)+(2*5)+(1*4)=152
152 % 10 = 2
So 1346702-54-2 is a valid CAS Registry Number.
1346702-54-2Relevant academic research and scientific papers
SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS
-
, (2012/09/21)
The present invention relates to substituted 6,5 -fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Identification of potent, selective, cell-Active inhibitors of the histone lysine methyltransferase EZH2
Verma, Sharad K.,Tian, Xinrong,Lafrance, Louis V.,Duquenne, Céline,Suarez, Dominic P.,Newlander, Kenneth A.,Romeril, Stuart P.,Burgess, Joelle L.,Grant, Seth W.,Brackley, James A.,Graves, Alan P.,Scherzer, Daryl A.,Shu, Art,Thompson, Christine,Ott, Heidi M.,Van Aller, Glenn S.,MacHutta, Carl A.,Diaz, Elsie,Jiang, Yong,Johnson, Neil W.,Knight, Steven D.,Kruger, Ryan G.,McCabe, Michael T.,Dhanak, Dashyant,Tummino, Peter J.,Creasy, Caretha L.,Miller, William H.
supporting information, p. 1091 - 1096 (2013/02/23)
The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, SAM-competitive, and cell-Active EZH2 inhibitors, including GSK926 (3) and GSK343 (6). These compounds are small molecule chemical tools that would be useful to further explore the biology of EZH2.
